GC
UTMD icon

Guggenheim Capital’s Utah Medical Products UTMD Stock Holding History

Guggenheim Capital’s Portfolio UTMD Stock Details UTMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$273K Buy
+3,951
New +$263K ﹤0.01% 1547

Other funds holding UTMD

BIP
Brandes Investment Partners La Jolla, California $14.3B AUM 23.11% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
MA
Minerva Advisors Bala Cynwyd, Pennsylvania $158M AUM 42.05% 1-Year Est. Return
Hotchkis & Wiley Capital Management
Hotchkis & Wiley Capital Management Los Angeles, California $34.3B AUM 22.63% 1-Year Est. Return
RHJA
Rice Hall James & Associates San Diego, California $2.05B AUM 43.16% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Guggenheim Capital's UTMD Position: Q2 2026 in Review

Guggenheim Capital opened a new position in Utah Medical Products (UTMD) in Q2 2026: 3,951 shares worth $273K. The stake represents ﹤0.01% of the portfolio and ranks #1547 among its holdings.

114 funds tracked by Wall St. Rank hold UTMD as of Q2 2026.

  • Guggenheim Capital held 3,951 shares of Utah Medical Products worth $273K as of Q2 2026.
  • Utah Medical Products was a new Guggenheim Capital position in Q2 2026.
  • Utah Medical Products made up ﹤0.01% of Guggenheim Capital's portfolio in Q2 2026, its #1547 holding.
  • 114 funds tracked by Wall St. Rank held Utah Medical Products as of Q2 2026.

Based on Guggenheim Capital's 13F filing for Q2 2026, filed 12 Aug 2026.